Medlab Clinical to begin trials of cannabis based medicines

Medlab Clinical (ASX:MDC) has received approvals to begin human trials of two different cannabis based medicines – NanaBis and NanaBidial.

NanaBis is packaged as a mouth spray and will be clinically tested in advanced stage cancer patients with intractable pain.

The drug is expected to meet a global need for better pain management, with research having shown cancer pain was an increasingly widespread condition.

Recent statistics regarding cancer pain indicate it is prevalent in 64% of patients with metastatic or advanced-stage disease and that for one in two patients with cancer, it is undertreated.

With the recent U.S. crackdown on opioid abuse, there is a significant need for better, efficacious treatment.

NanaBidial comprises cannabidiol derived from marijuana and is indicated for chemotherapy induced nausea and vomiting, with a secondary endpoint in patients suffering seizures.

The drug is intended to be made available to general practitioners so it would give many

... read more at: http://www.proactiveinvestors.com.au/companies/news/179427/medlab-clinical-to-begin-trials-of-cannabis-based-medicines-179427.html

Leave a Reply

Your email address will not be published. Required fields are marked *